travellinglight/iStock via Getty Images
- The US FDA has approved Biogen (BIIB) and Eisai’s (ESALF) (ESAIY) Leqembi Iqlik (lecanemab), a subcutaneous version of its Alzheimer’s treatment Leqembi, that can be administered for initiation and maintenance dosing, as well as at-home use.
- The initiation dose is
